A new artificial intelligence (AI) algorithm can help identify babies with genetic forms of cholestasis, including progressive familial intrahepatic cholestasis (PFIC), using data from…
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
A new study has uncovered a key mechanism behind the liver scarring seen in biliary atresia (BA), a rare liver disease in infants. Two…
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…
Adding vitamin D to ursodeoxycholic acid (UDCA) treatment is superior to UDCA alone at reducing symptoms, liver damage markers, and liver scarring in previously untreated…
Low levels of vitamin D by-products, or metabolites, in the blood are indicative of more severe liver damage in cholestasis, according to a small…
Enrollment is nearly complete in a Phase 2b clinical trial that’s testing Corcept Therapeutics‘ experimental oral therapy miricorilant in people with metabolic-associated steatohepatitis (MASH),…
An unreported mutation in the JAG1 gene was identified as the likely cause of Alagille syndrome in a 28-year-old woman, a case report from…
About 74,000 babies are born each year with the virus that causes hepatitis C, and more than 23,000 of them may still have the…
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis (PSC) who do not have…
